Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

BACKGROUND: The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mutations in the BRAF gene, inhibitors designed speci...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Crespo-Rodriguez, Eva, Bergerhoff, Katharina, Bozhanova, Galabina, Foo, Shane, Patin, Emmanuel C, Whittock, Harriet, Buus, Richard, Haider, Syed, Muirhead, Gareth, Thway, Khin, Newbold, Kate, Coffin, Robert S, Vile, Richard G, Kim, Dae, McLaughlin, Martin, Melcher, Alan A, Harrington, Kevin J, Pedersen, Malin
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2020
Schlagworte:
Oncolytic and Local Immunotherapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7445339/
https://ncbi.nlm.nih.gov/pubmed/32759235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000698
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge